December 12, 2022
VIA EDGAR SUBMISSION
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Attention: Doris Stacey Gama
| Re: | Cue Biopharma, Inc. |
Registration Statement on Form S-3
File No. 333-268687
Request for Acceleration
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cue Biopharma, Inc. hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-268687), so that it may become effective at 4:00 p.m., Eastern Time, on December 14, 2022, or as soon as practicable thereafter.
| Very truly yours, | ||
| CUE BIOPHARMA, INC. | ||
| By: | /s/ Kerri-Ann Millar | |
| Name: Kerri-Ann Millar | ||
| Title: Chief Financial Officer | ||